KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk.

Madhusree Singh

Ann Intern Med 175(3) JC34

PMID35226523
PMCID-
DOI10.7326/J22-0009
发表日期2022-02-28
摘要

摘要

Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398:1811-24. 34672967.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。